# Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

> **NCT05391022** · PHASE1 · COMPLETED · sponsor: **Constellation Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Advanced Malignancies
- Solid Tumor
- Hematological Malignancy

## Interventions

- **DRUG:** Pelabresib

## Key facts

- **NCT ID:** NCT05391022
- **Lead sponsor:** Constellation Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-20
- **Primary completion:** 2023-03-08
- **Final completion:** 2024-02-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391022, "Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05391022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*